Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | PADI3 | Q9ULW8 | 2/20 | 0.44 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183707 | 0.86 | ERN1 (0.61) | AOC3ERN1CFD | |
| SCHEMBL3948564 | 0.86 | PLAAT3 (0.50) | AOC3TRIM24TRIM33DRD1ALDH1A1 | |
| SCHEMBL27592964 | 0.85 | AOC3 (0.48) | AOC3CYP2D6CYP2C9TSHRERN1 | |
| SCHEMBL6478104 | 0.84 | TSHR (0.50) | AOC3CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL6204393 | 0.84 | ROCK2 (0.54) | AOC3 | |
| SCHEMBL2454247 | 0.83 | AOC3 (0.59) | AOC3CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL209625 | 0.83 | CYP2D6 (0.54) | AOC3TRIM24TRIM33CYP1A2CYP2D6 | |
| SCHEMBL2216638 | 0.82 | HPGDS (0.49) | AOC3CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL20497351 | 0.82 | SRC (0.58) | AOC3CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL6243284 | 0.80 | HDAC1 (0.51) | AOC3DRD1PADI3PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973063-B2 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-07-05 | — | — | US | disclosed |
| EP-1742608-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR(GAMMA) TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-02-11 | — | — | US | disclosed |
| US-7626054-B2 | Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-7294639-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-17 | — | — | US | disclosed |
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-7122564-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-17 | — | — | US | disclosed |
| EP-1458697-B1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RES & DEV (FR) | 2006-09-06 | — | — | EP | disclosed |
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | disclosed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | disclosed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | disclosed |
| EP-1458697-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | Galderma Research & Development, S.N.C. (FR) | 2004-09-22 | — | — | EP | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| WO-2003055867-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-07-10 | — | — | WO | disclosed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112070-A1 | Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | AOC3 2240/4885TRIM24 3733/4885TRIM33 4222/4885 |
| US-20070043046-A1 | Biaromatic ligand activators of PPARGAMMA receptors | PPARG, PPARA, PPARD | AOC3 2037/4885TRIM24 3463/4885TRIM33 3928/4885 |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | AOC3 1747/4885TRIM24 3617/4885TRIM33 3945/4885 |
| US-20100035988-A1 | Methods for activating PPAR gamma-type receptors | PPARG, PPARA, PPARD | AOC3 2134/4885TRIM24 3867/4885TRIM33 3687/4885 |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | AOC3 2037/4885TRIM24 3463/4885TRIM33 3928/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | AOC3 1973/4885TRIM24 3271/4885TRIM33 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.